Treatment with aromatase inhibitors for breast cancer is associated with bone loss in postmenopausal women

被引：0
|
作者：
不详
机构：
来源：
Drugs & Therapy Perspectives | 2009年 / 25卷 / 10期
关键词：
D O I：
10.2165/0042310-200925100-00007
中图分类号：
学科分类号：
摘要：
Aromatase inhibitors are a component of the standard treatment of hormone receptor-positive breast cancer in postmenopausal women. However, their use is associated with accelerated bone loss and an increased rate of fractures, in what is already an at-risk population group. It is important to screen for and prevent aromatase inhibitor-associated bone los. © 2009 Adis Data Information BV. All rights reserved.
引用
收藏
页码：23 / 26
页数：3
相关论文
共 50 条
  • [21] Aromatase inhibitors and the risk of colorectal cancer in postmenopausal women with breast cancer
    Khosrow-Khavar, F.
    Yin, H.
    Barkun, A.
    Bouganim, N.
    Azoulay, L.
    ANNALS OF ONCOLOGY, 2018, 29 (03) : 744 - 748
  • [22] Aromatase inhibitors, efficacy and metabolic risk in the treatment of postmenopausal women with early breast cancer
    Gonnelli, Stefano
    Petrioli, Roberto
    CLINICAL INTERVENTIONS IN AGING, 2008, 3 (04): : 647 - 657
  • [23] Aromatase Inhibitors Evolution as Potential Class of Drugs in the Treatment of Postmenopausal Breast Cancer Women
    Avvaru, Stephen Paul
    Noolvi, Malleshappa N.
    Aminbhavi, Tejraj M.
    Chkraborty, Sudipta
    Dash, Ashutosh
    Shukla, Shyam S.
    MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2018, 18 (07) : 609 - 621
  • [24] Aromatase inhibitors and bone health in women with breast cancer
    Chien, Amy Jo
    Goss, Paul E.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (33) : 5305 - 5312
  • [25] Bone density screening in postmenopausal women with early-stage breast cancer on aromatase inhibitors
    Stratton, Jamie
    Hu, Xin
    Soulos, Pamela R.
    Davidoff, Amy J.
    Pusztai, Lajos
    Gross, Cary Philip
    Mougalian, Sarah Schellhorn
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [26] Bone health in a prospective cohort of postmenopausal women receiving aromatase inhibitors for early breast cancer
    Servitja, Sonia
    Nogues, Xavier
    Prieto-Alhambra, Daniel
    Martinez-Garcia, Maria
    Garrigos, Laia
    Jesus Pena, Maria
    de Ramon, Marta
    Diez-Perez, Adolfo
    Albanell, Joan
    Tusquets, Ignasi
    BREAST, 2012, 21 (01): : 95 - 101
  • [27] Erratum to: Guidance for the prevention of bone loss and fractures in postmenopausal women treated with aromatase inhibitors for breast cancer: an ESCEO position paper
    R. Rizzoli
    J. J. Body
    A. DeCensi
    J. Y. Reginster
    P. Piscitelli
    M. L. Brandi
    Osteoporosis International, 2012, 23 (11) : 2577 - 2577
  • [28] Aromatase Inhibitors as Solely Treatment in Postmenopausal Breast Cancer Patients
    Hille, Ursula
    Soergel, Philipp
    Laenger, Florian
    Schippert, Cordula
    Makowski, Lars
    Hillemanns, Peter
    BREAST JOURNAL, 2012, 18 (02): : 145 - 150
  • [29] Aromatase inhibitors for prevention of breast cancer in postmenopausal women: a narrative review
    Behan, Lucy Ann
    Amir, Eitan
    Casper, Robert F.
    MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2015, 22 (03): : 342 - 350
  • [30] Negative Impact of Aromatase Inhibitors on Proximal Femoral Bone Mass and Geometry in Postmenopausal Women with Breast Cancer
    Lee, Su Jin
    Kim, Kyoung Min
    Brown, J. Keenan
    Brett, Alan
    Roh, Yun Ho
    Kang, Dae Ryong
    Park, Byeong Woo
    Rhee, Yumie
    CALCIFIED TISSUE INTERNATIONAL, 2015, 97 (06) : 551 - 559
12345